• Return to Headlines

Relatively Low Projected Earnings Growth Detected in Shares of Biospecifics Tec in the Biotechnology Industry (BSTC, RGEN, ENTA, AMGN, MYGN)

By Amy Schwartz

Below are the three companies in the Biotechnology industry with the lowest projected earnings growth. The growth of earnings per share (current fiscal year estimated vs. last year actual) is important to gauge future profitability and relative value. Higher EPS growth generally justifies higher earnings multiples.

Biospecifics Tec ranks lowest with a projected earnings growth of 0.6%. Following is Repligen Corp with a projected earnings growth of 1.2%. Enanta Pharmaceu ranks third lowest with a projected earnings growth of 2.7%.

Amgen Inc follows with a projected earnings growth of 5.9%, and Myriad Genetics rounds out the bottom five with a projected earnings growth of 9.0%.

SmarTrend recommended that its subscribers protect gains by selling shares of Myriad Genetics on February 5th, 2018 by issuing a Downtrend alert when the shares were trading at $35.24. Since that call, shares of Myriad Genetics have fallen 17.5%. We are now looking for when a new Uptrend will commence and will alert SmarTrend subscribers in real time.

Keywords: lowest projected earnings growth biospecifics tec repligen corp enanta pharmaceu amgen inc myriad genetics

Ticker(s): BSTC RGEN ENTA AMGN MYGN